Activity of purine analogs against Leishmania donovani in vivo.

Abstract

The dose of orally administered 9-deazainosine calculated to suppress 50% of Leishmania donovani amastigotes in hamster livers was 19 mg/kg (body weight) per day; 96 to 99% of Leishmania organisms were eliminated from the liver and spleen of squirrel monkeys by 50 mg/kg per day. Because these activities were greater than that of the experimental clinical agent allopurinol and comparable to that of the classical agent parenteral pentavalent antimony, 9-deazainosine should be considered for clinical development for visceral leishmaniasis.

• Authors: J D Berman, W L Hanson, J K Lovelace, V B Waits, J E Jackson, W L Chapman Jr, R S Klein
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 31 Issue 1 Pg. 111-3 (Jan 1987) ISSN: 0066-4804 [Print] United States
• PMID: 3566235 (Publication Type: Journal Article)

Chemical References

• Formycins
• Organometallic Compounds
• Guanosine
• 3-deazaguanosine
• Inosine
• Allopurinol
• Meglumine
• Meglumine Antimoniate
• 9-deazainosine

Topics

• Administration, Oral
• Allopurinol (administration & dosage, pharmacology)
• Animals
• Cricetinae
• Formycins (administration & dosage, pharmacology)
• Guanosine (administration & dosage, analogs & derivatives, pharmacology)
• Injections, Intramuscular
• Inosine (administration & dosage, analogs & derivatives, pharmacology)
• Leishmania donovani (drug effects)
• Leishmaniasis, Visceral (drug therapy, parasitology)
• Liver (parasitology)
• Male
• Meglumine (administration & dosage, pharmacology)
• Meglumine Antimoniate
• Mesocricetus
• Organometallic Compounds (administration & dosage, pharmacology)
• Saimiri
• Spleen (parasitology)